Jerome Boyd-Kirkup
Chief Scientific Officer Callio Therapeutics
Seminars
Tuesday 13th October 2026
Harnessing the Promise of Dual Payload ADCs to Combat Resistance to Traditional ADCs
2:00 pm
- Designing multi-mechanism complementary dual payload ADCs to drive deep and durable responses across a broad range of solid tumors
- Pioneering the next generation of dual payload ADCs featuring rationally selected payload combinations designed to overcome treatment resistance to single payload ADCs
- Advancing lead dual payload ADC, CLIO-8221, currently in clinical trials, and additional programs in IND-enabling studies
